Related Experiment Video
Updated: Aug 11, 2025
Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
Rational design of poly-L-glutamic acid-palbociclib conjugates for pediatric glioma treatment
Tetiana Melnyk1, Esther Masiá2, Oleksandr Zagorodko1
1Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, Valencia 46012, Spain.
Abstract:
Brain tumors represent the second most common cause of pediatric cancer death, with malignant gliomas accounting for ∼75% of pediatric deaths. Palbociclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has shown promise in phase I clinical trials of pediatric patients with progressive/refractory brain tumors using the oral administration route; however, pharmacokinetic limitations and toxicity issues remain. We synthesized a family of well-defined linear and star-shaped polyglutamate (PGA)-palbociclib conjugates using redox-sensitive self-immolative linkers to overcome limitations associated with free palbociclib. Exhaustive characterization of this conjugate family provided evidence for a transition towards the formation of more organized conformational structures upon increased drug loading. We evaluated the activity of conjugates in patient-derived glioblastoma and diffuse intrinsic pontine glioma cells, which display differing reducing environments due to differential glutathione expression levels. We discovered that microenvironmental parameters and the identified conformational changes determined palbociclib release kinetics and therapeutic output; furthermore, we identified a star-shaped PGA-palbociclib conjugate with low drug loading as an optimal therapeutic approach in diffuse intrinsic pontine glioma cells.
Insights
New polyglutamate-palbociclib conjugates show promise for treating pediatric brain tumors. A star-shaped conjugate optimized drug delivery and therapeutic output in diffuse intrinsic pontine glioma cells.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Malignant gliomas are a leading cause of pediatric cancer mortality.
- Palbociclib (a CDK4/6 inhibitor) shows early promise for pediatric brain tumors but faces pharmacokinetic and toxicity challenges.
- Current treatments for pediatric brain tumors, including glioblastoma and diffuse intrinsic pontine glioma, have limited efficacy.
Purpose of the Study:
- To develop novel polyglutamate-palbociclib conjugates to overcome limitations of free palbociclib.
- To investigate the impact of conjugate structure and drug loading on drug release and therapeutic efficacy.
- To identify an optimal conjugate formulation for treating specific pediatric brain tumors.
Main Methods:
- Synthesis of linear and star-shaped polyglutamate-palbociclib conjugates using redox-sensitive linkers.
- Characterization of conjugate structure, including conformational changes with drug loading.
- Evaluation of conjugate activity in patient-derived glioblastoma and diffuse intrinsic pontine glioma cells with varying glutathione levels.
- Assessment of drug release kinetics influenced by microenvironmental parameters.
Main Results:
- Conjugate formation showed increased structural organization with higher drug loading.
- Conjugate activity was dependent on microenvironmental factors and conformational changes.
- A star-shaped polyglutamate-palbociclib conjugate with low drug loading demonstrated optimal efficacy in diffuse intrinsic pontine glioma cells.
- Differential glutathione levels in glioblastoma and diffuse intrinsic pontine glioma cells influenced drug release and therapeutic output.
Conclusions:
- Polyglutamate-palbociclib conjugates offer a potential strategy to improve pediatric brain tumor therapy.
- Conjugate design, drug loading, and tumor microenvironment are critical for therapeutic success.
- A specific star-shaped conjugate represents a promising therapeutic candidate for diffuse intrinsic pontine glioma.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014